Alex Roepers on two deep-value special situations: $DCH and $NOMD

Summary

• Alex Roepers has made DCH—the just-closed American Axle/Dowlais merger, trading at $6.32 on the NYSE—a core Atlantic position, arguing the combined ~$10–11B-revenue supplier can earn “buck 50” to ~$2 per share. Even at a very low multiple, “you’re looking at a double or triple on the stock in the next, let’s say, year and a half to two years,” and by Andrew Walker’s math it trades near 5x adjusted free cash flow, so the company “might generate their entire market cap in free cash flow over the next four to five years.”
• The $300M synergy target is the load-bearing assumption, and Roepers calls it “very achievable” at just 3% of combined sales. The buckets: ~$90M of SG&A (public-company costs, duplicate offices), ~50% from purchasing scale, plus footprint optimization across ~170 plants; Roepers says management was already at roughly $35M after the first few months against a hoped-for $100M run-rate by the end of 2026—though Atlantic models roughly zero or very little free cash flow this year on integration and deal costs, with 2027–28 as the harvest.
• Walker’s biggest worry is governance, not the business: a CEO who owns under 1%, named the company after himself, and was earning roughly $12M a year before a one-time ~$12M PSU grant while the stock sat flat-to-down for five years—“I’m worried these guys are going to be empire builders.” The offsetting “dark arts” signal: a Feb. 3, 2026 8-K PSU grant that only starts vesting at $12 a share by the end of 2029, topping out at $22. Roepers shares the irritation but won’t “steer myself away from a great value stock because of that irritation” — and warns “our agitation, our activism goes way up when a stock is not doing what it’s supposed to do.”
• Nomad Foods (NOMD, $10.21, down from $30 in 2021 and recently cut in half) is the pick Roepers is more eager to pitch: ~$3–3.5B sales, ~$1.50 forecast EPS, under 7x EBITDA, and a 7%+ dividend yield. Well-known, often market-leading European frozen-food brands including Birds Eye, Iglo, and Findus; insider Noam Gottesman buying a large number of shares around $10; and PE-takeout math — “we like it from every angle.”
• Both treat Nomad as “a show-me story”: Aldi private label is taking share, the old CEO left, and Walker says the new CEO has kitchen-sunk everything — plants “20, 30, 40% utilized,” reinvestment needed in marketing and R&D. Walker reads that as a classic new-CEO setup ahead of a heavily teased fall analyst day, backed by category durability: “I’m pretty sure British kids are going to be eating frozen fish fingers 30 years from now.”
• The shared cleanup items: Walker estimates Nomad’s add-backs run ~20% of reported earnings (“this is add-back city”), which Roepers agrees “needs to change,” and Walker floats cutting a ~$90M annual dividend at roughly 6x earnings rather than buying back stock. Roepers would keep the $0.17/quarter dividend, says the company is not borrowing to fund it, expects leverage below 3x by 2027, and sees the stock at $15–20 with the yield compressing to ~4.5%.
• Both names carry a European discount, which Roepers treats as opportunity rather than taint—with a memorable aside that SpaceX is the true governance horror: “massively overvalued… a grotesque governance situation,” making Dauch’s sins “pretty minor in that perspective.” His summary on the pair: solid businesses, manageable balance sheets, strong margin of safety — “potential doubles over the next 18 to 24 months.”

Deep dive

1. DCH extends Atlantic’s GKN playbook

• Roepers’ history with the asset goes back to 2018, when GKN was Atlantic’s largest European holding and the firm pushed to split aerospace from automotive; Melrose Industries’ hostile approach in 2019 unlocked value, Atlantic benefited and “sold the stock with the big gain,” then kept Melrose—which post-divestitures “was GKN Automotive and Aerospace once again”—and, with letters to the board, urged the 2023 split.
• Post-split, Melrose (aerospace) rose until “it became too expensive for us,” leaving an orphaned ~$5B business, Dowlais (the former GKN Automotive), “in the dog house as many other automotive parts companies were”—tepid results, little following. Atlantic was out of Dowlais when the American Axle merger was announced, but “it perked our interest right away.”
• The entry got better before it got worse: after the February 2026 close, management “kind of downplayed the near-term outlook and the stock got hit—which was even a better opportunity to add.” Atlantic built a core position in stages starting that month.

2. The setup: a $6 stock with $1.50–$2 of earnings power

• The combined company is roughly double Dowlais’ size—~$10–11B in sales, ~$1.5B LTM EBITDA, $5B+ net debt against a ~$1.5B market cap. Roepers’ aerospace metaphor: “It’s sitting, as far as we’re concerned, on the tarmac. It’s taxiing around.”
• His rough math: earnings power of “buck 50 to $2” per share on a $6.32 stock—“if they do a good job with the synergies, if things go a little bit their way economically, which I think they will, and they don’t have to go heroically… you’re looking at a double or triple in the next year and a half to two years.”
• Walker’s complementary valuation frame: ~5x adjusted free cash flow, meaning most of the value comes back in the very near term—“it’s not like you need much terminal value there.”

3. The governance fight that hasn’t started yet

• Walker’s pushback, in full: he expected the CEO who named the company after himself to own 30% like “the Ford family”—instead he owns under 1%, the board owns no stock, and he was earning roughly $12M a year before a one-time ~$12M PSU grant while the stock went nowhere for five years. “My biggest worry actually is I’m worried these guys are going to be empire builders… how many auto suppliers really work out well for shareholders?”
• Roepers’ partial defense of the name: good names are scarce—Continental spun out “Aumovio” (AMV0 GY), Aptiv split off a company “I still have trouble saying”—so “I’m with you, I don’t like it, but I’m also not going to steer myself away from a great value stock because of that irritation.” For perspective on self-dealing, he detours into SpaceX: “massively overvalued… a grotesque governance situation with Mr. Musk getting tons of shares before and after the deal”—steer “extremely clear” despite the engineered low-float launch.
• Walker’s “dark arts” evidence that management believes: the Feb. 3, 2026 8-K grants the CEO PSUs that only begin vesting at $12/share by the end of 2029—a double in under four years—scaling to $22, with the synergy timeline (majority done by the end of 2028) fitting inside the vesting window.
• Roepers’ conditional truce: “if the company performs extraordinarily well, these are less of an issue. The moment there is underperformance, these become huge issues… our agitation, our activism goes way up when a stock is not doing what it’s supposed to do.” Atlantic doesn’t do activism for its own sake: “we’re very simple people, we like to buy low, sell high, and move on to the next thing.”

4. Synergy math and the capital-allocation roadmap Atlantic will push

• The $300M breaks into buckets Roepers finds credible: ~$90M SG&A (public-company costs, workforce, duplicate engineering and offices), ~50% from purchasing scale and freight over three years, and operational optimization across ~170 plants. At 3% of $11B sales, “in very synergistic manufacturing companies, we think this is very achievable”—Roepers says roughly $35M had already been achieved after the first few months, with a hoped-for $100M run-rate by the end of the 11-month 2026.
• The cash-flow shape matters: Atlantic models near-zero or very little free cash flow in 2026 on integration and transaction costs, then two full harvest years. Capex runs ~$500M (~4.5–5% of sales) against ~$850M of D&A including purchase-price accounting—a $300M spread that depresses EPS. “We don’t care,” but Atlantic will push for an adjusted EPS presentation.
• The unsolicited-advice agenda, delivered “always respectful, because more things get done that way”: a capital markets day by early next year laying out a credible EPS roadmap, then buybacks once net debt/EBITDA falls below the stated 2.5x—though Roepers would personally like leverage lower first given the cyclicality; “if the shares are unappreciated, we will probably push on a pretty good allocation to share buybacks.”

5. Cycle, China, and tariffs—why the near-term cash absorbs the risk

• Roepers assumes no volume recovery: global passenger-car production is ~90M units versus the 120M he says investors were thinking about five years ago, with growth accruing to Chinese and Korean low-cost exporters—“you better have content in those cars as a supplier,” and the combined company does, with exposure to Chinese OEMs and Asian manufacturing.
• Walker’s tail-risk framing: “if America lowered all the tariffs right now, I think 100% of new car sales would be Chinese EVs”—but at 5x free cash flow, the thesis doesn’t need the decade. Roepers agrees on horizon: “we’re playing it for the next two or three years… it’s going to be blocking and tackling and integrating the company,” with the Canada/Mexico tariff situation largely exempt under USMCA and sales spread globally, including China.

6. Nomad: 5.5x earnings, 7% yield, and insiders buying the dip

• The tape: NOMD at $10.21, down from $30 in 2021 and a $15–20 range through 2022–2025, recently halved on “some weakness, some under-management… nothing major”—earnings only modestly down on cost inflation, destocking, and competition. The category itself is advantaged: meals are $2–3 cheaper than nonfrozen food, and 43% of shoppers see frozen as reducing waste.
• The numbers Roepers rattles off: ~$3–3.5B sales, ~$1.50 forecast EPS (5.5x), under 7x EBITDA, ~8.5–9x operating income, and a 7%+ dividend yield—“that is a value stock, in a non-cyclical area with some growth to it. It is a takeover candidate. You have insiders buying… we like it from every angle.” The two key shareholders include Noam Gottesman, who recently bought a large number of shares around $10, and the old hedge-fund-style performance structure on their shares is gone—“that’s a good thing.”
• Why he’ll pitch it now: “I don’t like to talk on a podcast about a stock that’s already worked. I like to talk about another stock like this that’s on the tarmac, taxiing around, and people can still jump on board.” He also sketches the PE math: redirect dividend cash flow and cut corporate costs, “refinance the whole thing… there’s many ways to win here.”

7. The show-me story: bear case, new CEO, and Franklin’s attention

• Walker’s bear inventory: the old CEO who put Nomad together left at year-end, Aldi and private label are taking share, and the “nine years in a row outgrowing the category” slide quietly ignores the year everything fell off a cliff. Roepers doesn’t dodge: “it is a show-me story, for sure—but I think you’re getting paid to wait… the odds are very much stacked in our favor even under pretty conservative and tepid assumptions,” with near-term margins pressured by marketing and R&D reinvestment.
• Walker’s setup read—the bull case hiding in the kitchen-sink: the new CEO reset everything on his first earnings report, said plants were “20, 30, 40% utilized” and that they “dropped the ball on pricing,” and has teased a fall analyst day at four separate appearances. “Classic CEO taking over, kitchen-sinking everything, and then getting the story really sexy”—in a business where “I’m pretty sure British kids are going to be eating frozen fish fingers 30 years from now.”
• Walker relays a concern from friends that Franklin’s APi Group stake is worth more than $1B versus probably ~$100M in Nomad, so APi may receive more of his focus. Roepers admits he hasn’t spoken to Franklin but pushes back: he speculates that recouping lost value matters “for ego as well—their names are attached to this company… It would have concerned me if they were selling here. In fact, the opposite happened.” Walker’s historical caveat is that he believes Franklin has essentially only sold Jarden—which Walker thinks Franklin regretted—and then went activist on Newell roughly 13 months later.

8. Clean the numbers, question the dividend, and don’t fear the European discount

• Walker estimates Nomad’s “add-back city” restructuring and transformation add-backs run ~20% of presented earnings, and Roepers fully concedes: “I totally agree… it should definitely be lower than 20% of reported earnings. If that’s been the trend, that’s not good. It needs to change,” alongside improving leverage, share, and sales trends from a CEO “in there at less than a year.”
• On the dividend, they split: Walker floats slashing it and retiring “an extra 12% of the shares at 10”; Roepers would hold the $0.17/quarter (~$90M/year), argues the company has excess cash after the dividend rather than borrowing to fund it, expects debt below 3x by 2027, and says that if execution lands “the stock will go to 15 to 20” with the yield compressing to ~4.5%.
• On Walker’s “taint” question—whether European exposure is the shared X-factor discount—Roepers won’t make too much of it: DCH is really “an American company with very strong international presence,” well under half European, while all-European Nomad could benefit from a Ukraine-Russia resolution through further expansion and market-share gains in Eastern markets. His close on the pair: strong margin of safety, improving balance sheets, “potential doubles over the next 18 to 24 months.”